Law360, New York (May 09, 2012, 1:01 PM ET) -- On March 26, the U.S. Supreme Court remanded the Myriad Genetics Inc. gene patenting case to the Federal Circuit for reconsideration in light of the Supreme Court’s unanimous decision in Mayo Collaborative Services v. Prometheus Laboratories, in which the court held that two patents on a method to titrate thiopurine drugs are invalid insofar as they cover unpatentable subject matter.
The Mayo decision has potentially enormous long-term consequences for the biotechnology and diagnostic products segments of the heath care industry, since it was held that laws...
What's Next In The Myriad Genetics Case?
To view the full article, take a free trial now.
